Literature DB >> 23581515

Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.

N Narula1, D Charleton, J K Marshall.   

Abstract

BACKGROUND: The impact of peri-operative use of TNFα antagonists on post-operative complications such as infection and wound healing is controversial. AIM: To conduct a systematic review and meta-analysis to assess the impact of peri-operative use of TNFα antagonists on post-operative complications such as infection and wound healing in patients with inflammatory bowel disease (IBD).
METHODS: A literature search identified studies that investigated post-operative outcomes in patients with IBD using TNFα antagonists. The primary outcome was the rate of post-operative infectious complications. Secondary outcomes included the rates of non-infectious complications and total complications. Odds ratios (OR) with 95% confidence intervals (CI) are reported.
RESULTS: Overall, 18 studies with 4659 participants were eligible for inclusion. Patients with IBD using preoperative anti-TNFα therapies had significant increases in post-operative infectious [OR 1.56 (95% CI, 1.09-2.24)], non-infectious [OR 1.57 (95% CI, 1.14-2.17)] and total complications [OR 1.73 (95% CI, 1.23-2.43)]. Studies limited to patients with Crohn's disease demonstrated a statistically significant increase in infectious (OR 1.93, 95% CI 1.28-2.89) and total (OR 2.19, 95% CI 1.69-2.84) complications, and a trend towards increase in non-infectious complications (OR 1.73, 95% CI 0.94-3.17). Studies of patients with ulcerative colitis did not demonstrate significant increases in infectious (OR 1.39, 95% CI 0.56-3.45), non-infectious (OR 1.40, 95% CI 0.68-2.85), or total complications (OR 1.10, 95% CI 0.81-1.47).
CONCLUSION: Anti-TNFα therapies appear to increase the risk of post-operative complications. The increase in risk is small, and may well reflect residual confounding rather than a true biological effect. Nevertheless, physicians should exercise caution when continuing biological therapies during the peri-operative period.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23581515     DOI: 10.1111/apt.12313

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  38 in total

1.  The effect of pre-operative optimization on post-operative outcome in Crohn's disease resections.

Authors:  Alaa El-Hussuna; Igors Iesalnieks; Nir Horesh; Sabah Hadi; Yael Dreznik; Oded Zmora
Journal:  Int J Colorectal Dis       Date:  2016-10-26       Impact factor: 2.571

2.  Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis.

Authors:  YuJie Qiu; ZiCheng Zheng; Gang Liu; XinYu Zhao; AnQi He
Journal:  United European Gastroenterol J       Date:  2019-09-30       Impact factor: 4.623

3.  Immunosuppressed Patients with Crohn's Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database.

Authors:  Maria Abou Khalil; Jad Abou-Khalil; Jennifer Motter; Carol-Ann Vasilevsky; Nancy Morin; Gabriela Ghitulescu; Marylise Boutros
Journal:  J Gastrointest Surg       Date:  2019-03-18       Impact factor: 3.452

Review 4.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

Review 5.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

6.  Post-operative abdominal complications in Crohn's disease in the biological era: Systematic review and meta-analysis.

Authors:  Peter Waterland; Thanos Athanasiou; Heena Patel
Journal:  World J Gastrointest Surg       Date:  2016-03-27

Review 7.  Inflammatory bowel disease surgery in the biologic era.

Authors:  Linda Ferrari; Mukta K Krane; Alessandro Fichera
Journal:  World J Gastrointest Surg       Date:  2016-05-27

Review 8.  Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Motoi Uchino; Hiroki Ikeuchi; Junzo Shimizu; Hiroki Ohge; Seiji Haji; Toru Mizuguchi; Yasuhiko Mohri; Chizuru Yamashita; Yuichi Kitagawa; Katsunori Suzuki; Motomu Kobayashi; Masahiro Kobayashi; Fumie Sakamoto; Masahiro Yoshida; Toshihiko Mayumi; Koichi Hirata; Yoshio Takesue
Journal:  Surg Today       Date:  2020-04-10       Impact factor: 2.549

9.  Ileocecal Resection in Crohn's Disease: REMIND Group Study.

Authors:  Pavan Dhoble; Philip Abraham; Devendra Desai; Joshi Harshad; Ajinkya Sonambekar
Journal:  Am J Gastroenterol       Date:  2017-09       Impact factor: 10.864

10.  Perioperative Blood Transfusion and Postoperative Outcome in Patients with Crohn's Disease Undergoing Primary Ileocolonic Resection in the "Biological Era".

Authors:  Yi Li; Luca Stocchi; Yuanyi Rui; Ganglei Liu; Emre Gorgun; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.